相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials
A. S. Abbas et al.
DIABETES OBESITY & METABOLISM (2016)
Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus
Xiao-Wu Chen et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2015)
Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
Linda A. Gallo et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes
Stephan Matthaei et al.
DIABETES CARE (2015)
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
R. Chilton et al.
DIABETES OBESITY & METABOLISM (2015)
Empagliflozin as add-on to metformin in people with Type 2 diabetes
L. Merker et al.
DIABETIC MEDICINE (2015)
Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes in Taiwan A Population-Based Cohort Study
Yun-Ju Lai et al.
MEDICINE (2015)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETES CARE (2015)
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Hans-Ulrich Haering et al.
DIABETES CARE (2014)
Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with Type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study
M. Bajaj et al.
DIABETIC MEDICINE (2014)
Antihypertensive drugs and glucose metabolism
Christos V. Rizos et al.
WORLD JOURNAL OF CARDIOLOGY (2014)
Safety of dipeptidyl peptidase 4 inhibitors: a perspective review
Thomas Karagiannis et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2014)
Impact of Sodium Glucose Cotransporter 2 Inhibitors on Weight in Patients With Type 2 Diabetes Mellitus
Anthony H. Barnett
POSTGRADUATE MEDICINE (2013)
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
Bo Ahren
VASCULAR HEALTH AND RISK MANAGEMENT (2013)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus
G. Schernthaner et al.
DIABETES OBESITY & METABOLISM (2012)
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
M. -R. Taskinen et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study
D. R. Owens et al.
DIABETIC MEDICINE (2011)
Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain
E. Marrett et al.
DIABETES OBESITY & METABOLISM (2009)
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors
Leo Thomas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
分享论文
